Deutsche Bank analyst Gregg Gilbert raised his price target for Endo International to $11 from $10 after hosting investor meetings with management. The analyst sees the potential for "continued good" share performance if management continues to deliver on its plan. He cites higher Vasostrict sales assumptions following the recent price increase for his target boost and keeps a Buy rating on Endo. There could be upside to the company's outlook if additional generic competition to some important products does not materialize, Gilbert tells investors in a research note.